Ian M. Parnham, PhD’s Post

Only one week until our 'Overcoming Challenges in the Industrialisation of iPSC-derived therapies' webinar! Cell and Gene Therapy Catapult's Márcia F. Mata, will be discussing examples of how we are working to address key manufacturing challenges within the allogeneic cell therapy field; developing scalable, automated, and controlled processes to help bring these pioneering advanced therapies to patients will be discussed. Register now: https://buff.ly/3y9Z5XJ #iPSC #AdvancedTherapies #CellTherapies #GeneTherapies

Is your bioproduction workflow "tool'ed up"? Book a meeting with me at #advancedtherapies week to find out when is the right time AND how to do it!

Exciting Day 2 of Advanced Therapies Week down in Miami! So far, we’ve had the privilege to connect with some of the leading innovators in the field of Cell & Gene Therapy, one of the youngest fields in science today that holds a lot of promise for the future tomorrow. Between learning about innovative drug delivery methods to actual patient saving cell replacement therapy, this field holds so much promise for a better tomorrow. We are excited to sync up innovative strategies for how #CGT can prevent the progression of type two to type three diabetes. Share your interesting ideas below! #MindfulDiabetes #JOINTHECAMINO

Let's connect at #ISCT2024! Join our panel discussion on current state and future directions of process analytical technologies. We're elevating your process with cell collections, cell expansion, and fill-finish. Looking forward to seeing you there. #CellandGeneTherapy #CGT ISCT, International Society for Cell & Gene Therapy

Learn how fixed bed bioreactors like the Corning® Ascent® FBR System are helping to close the gap between research and manufacturing in the field of cell and gene therapy. This innovative system drastically increases capacity and yield, making it possible to produce large quantities of cells and viruses needed for therapeutic applications in a cost-efficient manner. Unlike traditional 2D surfaces, the Ascent FBR system allows adherent cells to grow in uniform 2D monolayers at high densities, greatly improving efficiency and reducing costs. Read more about it here: https://lnkd.in/g6kGS6XM #AscentFBR #CellTherapy #GeneTherapy

It was an absolute pleasure to attend and speak at the Gene Therapy Patient Engagement Summit again last week! A few takeaways: 📩 Direct and indirect engagement with the patient community should start even before the pre-clinical phase, as soon as a target condition has been identified   🤝 Early internal cross-functional alignment is critical to ensure patient advocacy is integrated into and considered in every functions' outputs   🏥 More consideration is needed when communicating the commitment of the long-term follow-up required post-gene therapy trials; for patients who have lived around hospital appointments and procedures for decades, we cannot underestimate the burden of having to continue this for a further 15 years    📺 When planning engagements and outreach to patients, it is critical to meet the communities where they're at

Heading to RESI / JPM conference today. If you want to hear how Opsin Biotherapeutics, Inc. is addressing the chronic pain epidemic using our disruptive neuromodulation therapy using gene therapy and light, reach out and we can set up a time to meet! #chronicpain #neuromodulation #spinalcordstimulation

🎦 Did you miss our latest webinar?🎦 Scott Tasker, our Head of Cell Therapy Applications, shared how Highway1 is improving cell sorting for Cell & Gene Therapy, by enhancing speed and reducing costs - all while minimising cell stress. We also compared technologies in a Treg manufacturing process, demonstrating 2x yield and 3.5x faster processing time. The recording has just gone live on our website for you to watch now⬇ https://lnkd.in/e2dFkm77 #cgt #celltherapy #cellsorting #flowcytometry

In the wake of last week's National Organ Day, a poignant inquiry surfaces regarding societal engagement—or the conspicuous absence thereof—in acknowledging not only this significant day but also other critical health awareness initiatives, such as Breast Cancer Awareness Month and Rare Disease Awareness. It beckons us to introspect on the societal disposition towards the dire scarcity of organs and the plight of countless individuals languishing in the interminable wait for the #giftoflife. This neglect raises profound ethical questions about our societal fabric's shift from altruism to a more egocentric ethos, prioritizing self-interest over communal welfare. Why does our collective conscience selectively navigate the myriad of health crises, amplifying some while inadvertently marginalizing others, such as the critical shortage of organ donors—a crisis claiming lives daily? This selective acknowledgment underscores a broader societal malaise, one characterized by a diminishing sense of communal responsibility and a burgeoning focus on individualism. It compels us to envisage the despair of those ensnared in the vicissitudes of organ shortage, their hopes for a new lease on life eclipsed by the grim reality of their situation. As we stand at this ethical crossroads, it is imperative to question when the tide of self-centeredness will ebb, paving the way for a resurgence of societal altruism. When will the pharmaceutical conglomerates and their executives transcend their avarice to champion organ donation advocacy genuinely? The exigency for a paradigm shift is palpable—a shift towards rekindling the flames of altruism, fostering a society where empathy and collective action illuminate the darkest recesses of human suffering. #organdonationawareness #SaveLivesGiveHope #DonateLife #BeAnOrganDonor #giftoflife AbbVie Pfizer Novartis Genentech Bristol Myers Squibb Astellas Pharma US Takeda Pharmaceuticals (formerly Nycomed) Merck United Therapeutics Corporation #socialcitenzship 

📢 HTID#6 News 📢   Join us at HTID#6 for a compelling discussion on "Success & Frustration: Personalized Medicine, Cell and Gene Therapy Trends"    This session will feature insights from Frédéric Desdouits (TreeFrog Therapeutics), Anne Moore, PhD (Roland Berger), Miguel Forte (Kiji Therapeutics) and David Venables (Laverock Therapeutics). Moderated by Elsy Boglioli Hofman, this session promises to delve into the latest trends and challenges in personalized medicine and advanced therapies.    Make sure not to miss out on the invaluable insights offered by these European experts !   #HTID6 #HealthcareInnovation #CellTherapy #GeneTherapy #MedicalAdvancements